A Common Human Skin Tumour is Caused by Activating Mutations in Beta-catenin
Authors
Affiliations
WNT signalling orchestrates a number of developmental programs. In response to this stimulus, cytoplasmic beta-catenin (encoded by CTNNB1) is stabilized, enabling downstream transcriptional activation by members of the LEF/TCF family. One of the target genes for beta-catenin/TCF encodes c-MYC, explaining why constitutive activation of the WNT pathway can lead to cancer, particularly in the colon. Most colon cancers arise from mutations in the gene encoding adenomatous polyposis coli (APC), a protein required for ubiquitin-mediated degradation of beta-catenin, but a small percentage of colon and some other cancers harbour beta-catenin-stabilizing mutations. Recently, we discovered that transgenic mice expressing an activated beta-catenin are predisposed to developing skin tumours resembling pilomatricomas. Given that the skin of these adult mice also exhibits signs of de novo hair-follicle morphogenesis, we wondered whether human pilomatricomas might originate from hair matrix cells and whether they might possess beta-catenin-stabilizing mutations. Here, we explore the cell origin and aetiology of this common human skin tumour. We found nuclear LEF-1 in the dividing tumour cells, providing biochemical evidence that pilomatricomas are derived from hair matrix cells. At least 75% of these tumours possess mutations affecting the amino-terminal segment, normally involved in phosphorylation-dependent, ubiquitin-mediated degradation of the protein. This percentage of CTNNB1 mutations is greater than in all other human tumours examined thus far, and directly implicates beta-catenin/LEF misregulation as the major cause of hair matrix cell tumorigenesis in humans.
Case report: Periorbital pilomatricoma: a rare benign skin tumor misdiagnosed as cellulitis.
Kumar R, Spadaro J, Kahana A Front Ophthalmol (Lausanne). 2025; 5:1503693.
PMID: 39926619 PMC: 11798964. DOI: 10.3389/fopht.2025.1503693.
Pediatric Pilomatrixomas: Four Atypical Clinical Presentations.
Melloni-Magnelli L, Gonzalez-Gaytan D, Sepulveda-Valenzuela M, Pena-Jimenez C, Martinez-Leija H, Villarreal E Plast Surg (Oakv). 2025; 33(1):133-138.
PMID: 39876865 PMC: 11770722. DOI: 10.1177/22925503231198098.
Baskaran S, Ravichandran J, Shree P, Thengumthottathil V, Karthikeyan B, Samal A ACS Omega. 2025; 10(2):1927-1942.
PMID: 39866619 PMC: 11755174. DOI: 10.1021/acsomega.4c06708.
Bach C, Tallet A, Bonenfant C, Lecomte T, Piton N, Samimi M Virchows Arch. 2024; .
PMID: 39579263 DOI: 10.1007/s00428-024-03986-3.
Genetic Tools for Cell Lineage Tracing and Profiling Developmental Trajectories in the Skin.
Nathans J, Ayers J, Shendure J, Simpson C J Invest Dermatol. 2024; 144(5):936-949.
PMID: 38643988 PMC: 11034889. DOI: 10.1016/j.jid.2024.02.006.